Kiniksa Pharmaceuticals International (KNSA) EBT (2021 - 2025)
Historic EBT for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $27.2 million.
- Kiniksa Pharmaceuticals International's EBT rose 47712.82% to $27.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year increase of 15330.91%. This contributed to the annual value of -$36.2 million for FY2024, which is 6033.05% up from last year.
- Latest data reveals that Kiniksa Pharmaceuticals International reported EBT of $27.2 million as of Q3 2025, which was up 47712.82% from $22.9 million recorded in Q2 2025.
- Kiniksa Pharmaceuticals International's EBT's 5-year high stood at $90.9 million during Q4 2022, with a 5-year trough of -$72.0 million in Q4 2023.
- Its 5-year average for EBT is -$6.9 million, with a median of -$9.4 million in 2023.
- Per our database at Business Quant, Kiniksa Pharmaceuticals International's EBT tumbled by 17923.51% in 2023 and then skyrocketed by 89292.53% in 2025.
- Quarter analysis of 5 years shows Kiniksa Pharmaceuticals International's EBT stood at -$43.8 million in 2021, then skyrocketed by 307.56% to $90.9 million in 2022, then plummeted by 179.24% to -$72.0 million in 2023, then surged by 76.43% to -$17.0 million in 2024, then soared by 259.94% to $27.2 million in 2025.
- Its EBT was $27.2 million in Q3 2025, compared to $22.9 million in Q2 2025 and $15.6 million in Q1 2025.